Close Menu

NEW YORK (GenomeWeb) – Biodesix today announced that its VeriStrat test has received a positive coverage decision from CareFirst Blue Cross Blue Shield.

VeriStrat is a blood-based proteomic test that helps guide treatment decisions for patients with non-small cell lung cancer.

CareFirst announced its position to extend coverage for the VeriStrat test in March and published a positive coverage policy earlier this week on its website, Biodesix said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.